Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines

Access this Article

Search this Article

Author(s)

    • Ma Chaoya
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Yamanaka Ryuya
    • Kyoto Prefectural University of Medicine, Graduate School for Health Care Science
    • Takeya Motohiro
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Komohara Yoshihiro
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Horlad Hasita
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Pan Cheng
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Yano Hiromu
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Ohnishi Koji
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Fujiwara Yukio
    • Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University
    • Matsuoka Masao
    • Department of Hematology, Graduate School of Medical Sciences, Kumamoto University|Laboratory of Virus Control, Institute for Virus Research, Kyoto University
    • Lee Aeju
    • International Research Organization for Advanced Science and Technology (IROAST), Kumamoto University|Magnesium Research Center, Kumamoto University
    • Niidome Takuro
    • Faculty of Advanced Science and Technology, Kumamoto University

Abstract

<p>Recent studies have indicated the significance of immune checkpoint molecules including programmed death-1 (PD-1), cytotoxic T-lymphocyte associated protein 4, and T-cell immunoglobulin and mucin domain-containing molecule-3 for anti-tumor immune responses. We previously investigated PD-1 ligand 1/2 (PD-L1/2) expression in lymphoma cell lines, and found that PD-L1/2 is expressed on the adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines. In the present study, we investigated whether the Stat3 inhibitor WP1066 abrogated PD-L1/2 expression in lymphoma cell lines. Incubation with WP1066 inhibited lymphoma cell growth and induced cell apoptosis. PD-L1/2 expression in the ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines was significantly abrogated by WP1066 treatment. These data indicated that a Stat3 inhibitor abrogated PD-L1/2 expression in lymphoma cells. Such an inhibitor is therefore considered to be useful for additional immunotherapy in patients with advanced lymphoma.</p>

Journal

  • Journal of Clinical and Experimental Hematopathology

    Journal of Clinical and Experimental Hematopathology 57(1), 21-25, 2017

    The Japanese Society for Lymphoreticular Tissue Research

Codes

  • NII Article ID (NAID)
    130005709510
  • Text Lang
    ENG
  • ISSN
    1346-4280
  • Data Source
    J-STAGE 
Page Top